NICE's TA1121 verdict tells clinicians to pick whichever ATTR-CM stabiliser, tafamidis or acoramidis, costs less.

Transthyretin amyloidosis (ATTR) is two commercial markets in one disease. ATTR cardiomyopathy (ATTR-CM) is served by oral TTR-tetramer stabilisers: tafamidis (Vyndaqel/Vyndamax, Pfizer), recommended by NICE in TA984 on the ATTR-ACT trial, and acoramidis (Beyonttra, licensed to Bayer, marketed as Attruby in the US by BridgeBio), recommended by NICE in TA1121 in January 2026 on ATTRibute-CM as the first direct stabiliser competitor. ATTR polyneuropathy (ATTR-PN) is held by Alnylam's RNA-based TTR silencers: patisiran (Onpattro, IV, NICE HST10) and vutrisiran (Amvuttra, SC, NICE TA868). Vutrisiran has since crossed into cardiomyopathy, recommended by NICE in TA1115, opening a stabiliser-versus-silencer contest inside ATTR-CM.

The UK commercial story is defined by NICE mechanics rather than US list-price dynamics. Every UK recommendation rests on a confidential commercial arrangement that sets the net NHS price below list; vutrisiran's list price alone is about £383,000 per patient per year. In TA1121, NICE went further: because acoramidis and tafamidis are clinically similar and treat the same population, NICE directs clinicians to use the least expensive of the two, a cost-minimisation directive that converts the contest into direct price competition. Access also diverges across the UK: a positive NICE appraisal carries a legal NHS funding obligation in England within 90 days, whereas Scotland requires separate SMC acceptance.

Two clinically similar stabilisers now compete on net price, not efficacy.

Five questions this report answers:

Q1 - How do oral TTR stabilisers and RNA silencers differ across ATTR-CM and ATTR-PN?

Q2 - What does acoramidis's TA1121 recommendation mean for the tafamidis franchise under NICE's cost-minimisation rule?

Q3 - How do NICE commercial arrangements and separate SMC Scotland assessment shape ATTR access?

Q4 - Why does vutrisiran's roughly £383,000 annual list price matter for NHS net pricing?

Q5 - What did vutrisiran's TA1115 cardiomyopathy recommendation add to the stabiliser-versus-silencer contest?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

Live report page:  https://axlrx.ai/attr-amyloidosis/uk/competitive-intelligence/

Thanks & Regards,

Mike W

hello@axlrx.ai

Website - https://axlrx.ai/